Form 4 for FHTX Foghorn Therapeutics Inc.
Accepted 2022-09-19 00:00:00 ET · period of report 2022-09-16 · accession 0001562180-22-006726 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-19 | 2022-09-16 | FHTX | GOTTSCHALK ADRIAN | CEO, Dir | M - OptEx | $0.54 | +40.0K | 186.5K | +27% | +$21.6K |
| D | 2022-09-19 | 2022-09-16 | FHTX | GOTTSCHALK ADRIAN | CEO, Dir | M - OptEx | $0.00 | -40.0K | 418.9K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-16 | M | A | 40,000 | $0.54 | 186,479 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-09-16 | M | D | 40,000 | $0.00 | 418,925 | D | $0.54 · — to 2027-05-29 | 40,000 Common Stock | (F2) The option vested as to 25% of the underlying shares of common stock on May 30, 2018, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter until the option was fully vested. |